ID   AREc32
AC   CVCL_1D32
SY   MCF7 AREc32
DR   ECACC; 16071902
DR   Wikidata; Q54750439
DR   Ximbio; 151014
RX   PubMed=17108137;
WW   http://www.cxrbiosciences.com/technologies/arec32-cell-line/
CC   Sequence variation: Homozygous for CDKN2A deletion (from parent cell line).
CC   Sequence variation: Heterozygous for PIK3CA p.Glu545Lys (c.1633G>A) (from parent cell line).
CC   Transfected with: UniProtKB; P08659; Firefly luciferase.
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): ECACC
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 14
ST   D21S11: 30
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 9
ST   D8S1179: 10,14
ST   FGA: 23,25
ST   Penta D: 12
ST   Penta E: 7,12
ST   TH01: 6
ST   TPOX: 9,12
ST   vWA: 14,15
DI   NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 25-02-19; Version: 7
//
RX   PubMed=17108137; DOI=10.1158/0008-5472.CAN-06-2298;
RA   Wang X.J., Hayes J.D., Wolf C.R.;
RT   "Generation of a stable antioxidant response element-driven reporter
RT   gene cell line and its use to show redox-dependent activation of nrf2
RT   by cancer chemotherapeutic agents.";
RL   Cancer Res. 66:10983-10994(2006).
//